Literature DB >> 1359541

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

C T Guy1, M A Webster, M Schaller, T J Parsons, R D Cardiff, W J Muller.   

Abstract

Overexpression and amplification of the neu (c-erbB2, ERBB2) protooncogene have been implicated in the development of aggressive human breast cancer. To directly assess the effect of mammary gland-specific expression of the neu protooncogene, transgenic mice carrying unactivated neu under the transcriptional control of the mouse mammary tumor virus promoter/enhancer were established. By contrast to the rapid tumor progression observed in several transgenic strains carrying the activated neu transgene, expression of unactivated neu in the mammary epithelium resulted in the development of focal mammary tumors after long latency. The majority of the mammary tumors analyzed expressed elevated levels of neu-encoded mRNA and protein. Overexpression of neu in the mammary tumors was also associated with elevated neu intrinsic tyrosine kinase activity and the de novo tyrosine phosphorylation of several cellular proteins. Interestingly, many of the tumor-bearing transgenic mice developed secondary metastatic tumors in the lung. These observations suggest that overexpression of the unactivated neu protein can induce metastatic disease after long latency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359541      PMCID: PMC50384          DOI: 10.1073/pnas.89.22.10578

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.

Authors:  C I Bargmann; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

3.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

Authors:  R M Hudziak; J Schlessinger; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

5.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.

Authors:  M C Paterson; K D Dietrich; J Danyluk; A H Paterson; A W Lees; N Jamil; J Hanson; H Jenkins; B E Krause; W A McBlain
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

6.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

Authors:  J A Drebin; V C Link; D F Stern; R A Weinberg; M I Greene
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

7.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

8.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

9.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  467 in total

1.  A new mutator phenotype in breast cancer?

Authors:  Johan G de Boer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 2.  The functions of cytokines and their uses in toxicology.

Authors:  J R Foster
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

3.  Transcriptional regulation of the protocadherin β cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching.

Authors:  Huabei Guo; Alison Nairn; Mitche dela Rosa; Tamas Nagy; Shaying Zhao; Kelley Moremen; Michael Pierce
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

4.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

5.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

6.  Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.

Authors:  Ekram Gad; Lauren Rastetter; Meredith Slota; Marlese Koehnlein; Piper M Treuting; Yushe Dang; Sasha Stanton; Mary L Disis
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

7.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

8.  Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.

Authors:  Shalini Jain; Xiao Wang; Chia-Chi Chang; Catherine Ibarra-Drendall; Hai Wang; Qingling Zhang; Samuel W Brady; Ping Li; Hong Zhao; Jessica Dobbs; Matt Kyrish; Tomasz S Tkaczyk; Adrian Ambrose; Christopher Sistrunk; Banu K Arun; Rebecca Richards-Kortum; Wei Jia; Victoria L Seewaldt; Dihua Yu
Journal:  Cancer Res       Date:  2015-09-17       Impact factor: 12.701

9.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Authors:  Jian Cao; Zongzhi Liu; William K C Cheung; Minghui Zhao; Sophia Y Chen; Siew Wee Chan; Carmen J Booth; Don X Nguyen; Qin Yan
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

10.  A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.

Authors:  Hayley S Ma; Bibhav Poudel; Evanthia Roussos Torres; John-William Sidhom; Tara M Robinson; Brian Christmas; Blake Scott; Kayla Cruz; Skylar Woolman; Valerie Z Wall; Todd Armstrong; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2019-01-14       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.